Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90)
- 1 June 1997
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (7), 1017-1024
- https://doi.org/10.1016/s0959-8049(97)00105-6
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancerAnnals of Oncology, 1996
- A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancerAnnals of Oncology, 1996
- PP-8-25 The clinical relevance of static disease for 6 months on endocrine therapy in patients with breast cancerEuropean Journal Of Cancer, 1996
- Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.Journal of Clinical Oncology, 1994
- Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifenCancer, 1994
- Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate?Annals of Oncology, 1993
- FormestaneDrugs of the Future, 1993
- The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breastEuropean Journal of Cancer and Clinical Oncology, 1988
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896